United Therapeutics Stock Forecast for 2023 - 2025 - 2030
Updated on 02/04/2023
United Therapeutics Stock Forecast and Price Target
United Therapeutics's stock is projected to advance by 16.69% from the previous closing price if it reaches the average target of $295.00 by the year's end, as four reputable analysts recently projected. This potential upside is calculated on a high-end estimate of $375.00 and a low-end estimate of $150.00. If you're looking for information on United Therapeutics stock, consider checking out the forecasts for comparable firms such as NasdaqGS:AMGN.
16.69% Upside
United Therapeutics Fair Value Forecast for 2023 - 2025 - 2030
In the last two years, United Therapeutics's Price has grown, moving from $105.20 to $124.06 – an increase of 17.93%. For the following year, the 0 analysts predict that United Therapeutics's Fair Value will drop by 7.00%, reaching $115.38. In 2030, the professionals' prediction is that UTHR's Fair Value will decrease by 6.43%, reaching $116.08.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| PFE Stock Forecast | Pfizer Inc | Outperform |
3
|
$44.06 | $53.97 | 19.50% |
| NOVN Stock Forecast | Novartis | Hold |
10
|
CHF85.77 | CHF103.75 | 9.89% |
| AMGN Stock Forecast | Amgen Inc | Hold |
7
|
$245.17 | $268.00 | 13.39% |
| GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$84.50 | $87.30 | 4.14% |
| REGN Stock Forecast | Regeneron Pharmaceuticals Inc | Outperform |
2
|
$722.13 | $796.73 | 8.29% |
United Therapeutics Revenue Forecast for 2023 - 2025 - 2030
In the last two years, United Therapeutics's Revenue has grown, moving from $1.45B to $1.69B – an increase of 16.34%. For the following year, the 0 analysts predict that United Therapeutics's Revenue will drop by 8.78%, reaching $1.54B. In 2030, the professionals' prediction is that UTHR's Revenue will decrease by 8.13%, reaching $1.55B.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| VRTX Stock Forecast | Vertex Pharmaceuticals Inc | Outperform |
16
|
$301.02 | $323.74 | 8.30% |
| GSK Stock Forecast | GSK | Hold |
16
|
£1.44k | £16.95 | -98.88% |
| CE Stock Forecast | Celanese | Outperform |
13
|
$125.45 | $125.00 | -0.76% |
United Therapeutics Free Cash Flow Forecast for 2023 - 2025 - 2030
In the last two years, Free Cash Flow for United Therapeutics has grown by 264.45%, going from $-290.30M to $477.40M. According to the 0 analysts polled, in the next year, United Therapeutics's Free Cash Flow will fall by 16.65%, reaching $397.91M. By 2030, professionals believe that United Therapeutics's Free Cash Flow will have decreased by 12.91%, falling to $415.75M.
United Therapeutics Net Income Forecast for 2023 - 2025 - 2030
United Therapeutics's Net Income has seen growth In the last two years, going from $-104.50M to $475.80M – a gain of 555.31% The next year, 0 experts forecast that United Therapeutics's Net Income will decrease by 34.63%, reaching $311.01M. In 2030, professionals predict that United Therapeutics's Net Income will decrease by 26.33%, reaching $350.51M.
United Therapeutics EBITDA Forecast for 2023 - 2025 - 2030
United Therapeutics's EBITDA has grown in the last two years, jumping from $-131.70M to $736.80M – an increase of 659.45%. For the next year, 0 analysts project United Therapeutics's EBITDA to drop by 48.86%, reaching $376.77M. By 2030, professionals believe that United Therapeutics's EBITDA will decrease by 33.54%, reaching $489.64M – a concerning trend for the company.
United Therapeutics EBIT Forecast for 2023 - 2025 - 2030
In the last two years, United Therapeutics's EBIT has increased by 486.77%, going from $-177.60M to $686.90M. According to 0 prominent analysts, United Therapeutics's EBIT will fall by 52.66% in the next year, reaching $325.20M. By 2030, professionals believe that United Therapeutics's EBIT will decrease by 34.69%, reaching $448.62M – a concerning trend for the company.
United Therapeutics EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last two years, United Therapeutics's EPS has grown, moving from $12.94 to $15.26 – an increase of 17.93%. For the following year, the 0 analysts predict that United Therapeutics's EPS will drop by 7.00%, reaching $14.19. In 2030, the professionals' prediction is that UTHR's EPS will decrease by 6.43%, reaching $14.28.